Abstract

Background

The use of antithrombotic agents, including anticoagulants, antiplatelet agents, and thrombolytics has increased over the last decade and is expected to continue to rise. Although antithrombotic-associated intracranial hemorrhage can be devastating, rapid reversal of coagulopathy may help limit hematoma expansion and improve outcomes.

Methods

The Neurocritical Care Society, in conjunction with the Society of Critical Care Medicine, organized an international, multi-institutional committee with expertise in neurocritical care, neurology, neurosurgery, stroke, hematology, hemato-pathology, emergency medicine, pharmacy, nursing, and guideline development to evaluate the literature and develop an evidence-based practice guideline. Formalized literature searches were conducted, and studies meeting the criteria established by the committee were evaluated.

Notes

Acknowledgments

We would like to thank Zoe Oliver, MD and Frederick A. Zeiler, MD for their contributions to this document.

Compliance with Ethical Standards

Disclosures

D. Aisiku serves on the National Advisory Board for the Medicines Company, Dr. Alexandrov serves on the speakers bureau for Genentech. Dr. del Zoppo has received research funds from the NIH, Boehringer Ingelheim, and Novartis. He has served on advisory boards for Boehringer Ingelheim, Daiichi-Sankyo, and Novartis. Dr. Kumar has received support from Haemonetics. Dr. Stiefel serves as a consultant for Medtronic and Penumbra. The remaining authors have nothing to disclose.

van Ryn JS, Schmoll M, Pillu H, et al. Effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers: an exploratory marker of blood loss. Circulation. 2014;130(Suppl 2):18403.Google Scholar

Chargaff E, Olson KB. Studies on the chemistry of blood coagulation: studies on the action of heparin and other anti-coagulants; the influence of protamine on the anticoagulant effect in vivo. J Biol Chem. 1937;122:153–67.Google Scholar

Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost. 1995;73:439–43.PubMedGoogle Scholar

Funk DM. Coagulation assays and anticoagulant monitoring. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program; 2012:460–5.Google Scholar

Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:2001–23.PubMedCrossRefGoogle Scholar

Laulicht BB S, Jiang X, et. al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th Congress of the International Society on Thrombosis and Hemostasis, abstract 2013.Google Scholar